U.S. Dupixent Market Size, Share, Trends, Industry Analysis Report By Indication [Atopic Dermatitis (AD), Asthma, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)], By Distribution Channel - Market Forecast, 2025-2034

The U.S. dupixent market size is expected to reach USD 19.25 billion by 2034, according to a new study by Polaris Market Research. The report "U.S. Dupixent Market Size, Share, Trends, Industry Analysis Report By Indication [Atopic Dermatitis (AD), Asthma, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)], By Distribution Channel - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The U.S. Dupixent market refers to the commercial landscape for dupilumab, a biologic medication that targets specific proteins involved in type 2 inflammation. This market includes all aspects from the research and development of dupilumab, and its manufacturing, distribution, and sale, to its use by patients. Dupixent is a prescription-only medication primarily used to treat a range of chronic inflammatory conditions, including moderate-to-severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, and a specific type of chronic obstructive pulmonary disease. The market encompasses the entire value chain, involving pharmaceutical companies, healthcare providers, and the patients who benefit from this advanced therapy.

Pharmaceutical companies in the U.S. are allowed to market directly to consumers through TV, online, and print advertising. Sanofi and Regeneron, the makers of Dupixent, invest heavily in awareness campaigns that educate patients about symptoms and encourage them to speak to their doctors. These ads resonate with people suffering from chronic conditions, helping to drive doctor visits and prescriptions. Combined with digital outreach and physician engagement, this marketing strategy boosts demand by building brand recognition and trust among American consumers, giving Dupixent a strong edge in a competitive market.

In the U.S., doctors and patients report high satisfaction with Dupixent due to its strong track record in improving symptoms, reducing flare-ups, and avoiding the need for steroids or frequent hospital visits. Positive experiences lead to repeat prescriptions and more physicians recommending it as a first-line biologic therapy. Patients often stay on Dupixent long-term, which increases its lifetime value in the market. Word-of-mouth referrals and supportive clinical studies further encourage its use. This satisfaction level plays a major role in growing its popularity across multiple specialties in the U.S. healthcare system, thereby driving the growth.

U.S. Dupixent Market Report Highlights

The atopic dermatitis (AD) segment dominated with the largest share in 2024, as AD remained the largest indication driving Dupixent sales in the U.S.

The hospital pharmacies segment held the largest share in 2024, as these facilities handle complex or high-cost biologics such as Dupixent, especially for inpatient and specialty ambulatory care services facilities.

Key players in the market are Sanofi and Regeneron Pharmaceuticals.

Polaris Market Research has segmented the U.S. Dupixent market report on the basis of indication and distribution channel:

By Indication Outlook (Revenue - USD Billion, 2020-2034)

Atopic Dermatitis (AD)

Asthma

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Chronic Obstructive Pulmonary Disease (COPD)

Others

By Distribution Channel Outlook (Revenue - USD Billion, 2020-2034)

Hospital Pharmacies

Retail Pharmacies

Others